Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Medical Research Council |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00002658 |
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of different treatment regimens in treating patients who have acute myeloid leukemia.
Condition | Intervention | Phase |
---|---|---|
Cancer-Related Problem/Condition Leukemia |
Drug: amsacrine Drug: cyclophosphamide Drug: cytarabine Drug: daunorubicin hydrochloride Drug: etoposide Drug: filgrastim Drug: idarubicin Drug: mitoxantrone hydrochloride Drug: thioguanine Drug: tretinoin Procedure: allogeneic bone marrow transplantation Procedure: autologous bone marrow transplantation Procedure: peripheral blood stem cell transplantation Procedure: radiation therapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Active Control |
Official Title: | ACUTE MYELOID LEUKAEMIA TRIAL 12 |
Ages Eligible for Study: | 15 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
De novo or secondary acute myeloid leukemia of any morphologic type
PATIENT CHARACTERISTICS:
Age:
Performance status:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
United Kingdom, Wales | |
University of Wales College of Medicine | |
Cardiff, Wales, United Kingdom, CF14 4XN |
Study Chair: | Alan K. Burnett, MD, FRCP | The University of New South Wales |
Study ID Numbers: | CDR0000064208, MRC-LEUK-AML12, EU-95001 |
Study First Received: | November 1, 1999 |
Last Updated: | October 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00002658 |
Health Authority: | United States: Federal Government |
untreated adult acute myeloid leukemia adult acute erythroid leukemia (M6) adult acute myeloblastic leukemia without maturation (M1) adult acute myeloblastic leukemia with maturation (M2) adult acute promyelocytic leukemia (M3) adult acute myelomonocytic leukemia (M4) |
adult acute monoblastic leukemia (M5a) adult acute megakaryoblastic leukemia (M7) secondary acute myeloid leukemia adult acute monocytic leukemia (M5b) neutropenia adult acute minimally differentiated myeloid leukemia (M0) |
Leukemia, Monocytic, Acute Daunorubicin Acute myelomonocytic leukemia Amsacrine Cyclophosphamide Leukemia, Myeloid, Acute Di Guglielmo's syndrome Etoposide phosphate Leukemia Leukemia, Promyelocytic, Acute Neoplasm Metastasis Acute erythroblastic leukemia Acute myeloid leukemia, adult Acute myelocytic leukemia |
Etoposide Cytarabine Thioguanine Acute promyelocytic leukemia Acute myelogenous leukemia Leukemia, Myeloid Leukemia, Myelomonocytic, Acute Neutropenia Idarubicin Leukemia, Erythroblastic, Acute Tretinoin Mitoxantrone Acute monoblastic leukemia |
Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Neoplasms by Histologic Type Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Antibiotics, Antineoplastic Antiviral Agents Immunosuppressive Agents |
Pharmacologic Actions Neoplasms Sensory System Agents Therapeutic Uses Myeloablative Agonists Peripheral Nervous System Agents Analgesics Antineoplastic Agents, Alkylating Antirheumatic Agents Central Nervous System Agents Alkylating Agents |